4 hours ago
1
Dmitry Vinogradov
Piper Sandler has initiated GeneDx (NASDAQ:WGS) at overweight saying that the genetic testing company is addressing a rare disease testing market that has room to grow.
The firm set a $110 price target (~29% upside based on July 8 close).
English (US) ·